Meeting
2017 ASCO Annual Meeting
Analysis of circulating tumor DNA (ctDNA) in pseudoprogression in anti-PD1 treated metastatic melanoma (MM).
Authors
Jenny HJ Lee
Macquarie University, Sydney, Australia
Jenny HJ Lee , Georgina V. Long , Alexander M. Menzies , Alexander David Guminski , Richard Kefford , Helen Rizos , Matteo S. Carlino
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9546)
DOI
10.1200/JCO.2017.35.15_suppl.9546
Abstract #
9546
Poster Bd #
154
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Bim as a predictive T-cell biomarker for response to anti-PD-1 therapy in metastatic melanoma (MM).
First Author: Roxana Stefania Dronca
Poster
2023 ASCO Annual Meeting
In silico approaches to patient selection: Credentialing elraglusib as a novel treatment in metastatic melanoma resistant to checkpoint inhibitors.
First Author: Joseph McDermott
Poster
2020 ASCO Virtual Scientific Program
Clinical value of noninvasive biomarkers reflecting a collagen-rich stroma in metastatic melanoma patients treated with anti-PD1 therapy.
First Author: Christina Jensen
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Autoimmune toxicities with anti-PD-1 treatment of metastatic melanoma in predominantly older patients: A single institutional experience.
First Author: Harsh V Parmar